Canada has approved Boey®, the first rapid-onset and short-duration botulinum neurotoxin serotype E, for temporarily improving moderate to severe glabellar (frown) lines. Developed by Allergan Aesthetics, Boey® offers results visible as early as eight hours after treatment, lasting about two to three weeks, providing a new option for patients hesitant about long-term effects of facial injectables. Allergan plans to train healthcare professionals and launch the product commercially soon, with approvals pending in other countries. This approval marks a significant advancement in aesthetic medicine, expanding treatment choices for clinicians and patients.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
